Quantum Biopharma Ltd. Class B Subordinate Voting Shares
QNTMQuantum Biopharma Ltd. is a biotechnology company focused on developing and commercializing innovative therapies in the biopharmaceutical sector. The company aims to leverage advanced scientific research to create targeted treatments, particularly in areas such as neurodegenerative diseases and other unmet medical needs. Its Class B subordinate voting shares (QNTM) represent equity ownership and voting rights within the company, offering investors opportunities to participate in its growth and development efforts.
Company News
Quantum BioPharma announced that its Lucid-MS (Lucid-21-302) investigational drug for multiple sclerosis treatment has been placed on clinical hold by the FDA pending submission of additional information. The company believes the issues are addressable and plans to submit a response package. Previously disclosed timelines for FDA review, Phase 2 ...
Quantum BioPharma has engaged two marketing firms—Senergy Communications Capital Inc. and King Tide Media LLC—to provide marketing and investor awareness services starting May 2026. The company will pay USD $150,000 to Senergy and USD $125,000 to KTM for corporate branding, social media, and advertising initiatives on one-month contracts with...
Quantum BioPharma Ltd. granted 35,000 stock options to employees and consultants, exercisable at CA$6.50 for five years. The options vest immediately and are subject to a four-month hold period. The grant was made under the company's shareholder-approved stock option plan.
Quantum BioPharma Ltd. has closed the first tranche of its debenture unit offering, raising $3.75 million CAD from 3,750 Debenture Units. The company also completed an initial batch of debt settlement by issuing 370,457 Class B subordinate voting shares to settle approximately $1.12 million CAD of debt owed to creditors and insiders. Proceeds wil...
Quantum BioPharma Ltd. announced revised terms for its Debenture Units offering following a decrease in its Class B subordinate voting share price. The company reduced the conversion price per share to $3.00, increased warrant allocation to 333.33 per unit, and lowered the exercise price per warrant share to $3.75. The debt settlement will also b...
